Specific to this topic, in the global public health and infectious diseases and vaccines arena, we've got a long tradition in working in HIV, in TB, and many other diseases, like Zika and Ebola. We have a vaccines platform, where we are in the process of developing vaccines for Zika; we have actually 2M doses of an Ebola vaccine ready to deploy anytime there is a crisis - and those we developed and accelerated when there was a big Ebola crisis in 2015. We also have a vaccine for HIV, which is in clinical trials in South Africa. It's going to be tested in 2600 young girls and women in Sub-Saharan Africa, keeping fingers-crossed. In TB, we brought forward the first new mechanism of action in 40 years, there was a new compound and new break though and that works against multi-drug resistant TB
(MDR-TB). So for those when all hope is gone and near deathbed when resistant to all of the existing treatments, this particular medicine helps. Especially in South Africa, we have a wonderful collaboration with the government through clinical trials and also access programs, where we made our compound available for use and the transformation that has taken place in those patients is just extraordinary in terms of changing the trajectory of the mortality rates of MDR-TB, so much so that the South African government made a courageous move to put this medicine as part of its drug regimen against MDR-TB. So we have a huge footprint, and then in HIV we have three products which treat HIV, but in addition to that we have a long-acting injectable, we're working together with GSK ViiV.